BRD4 and posterior cortical atrophy: In combination with other therapies such as protein acetyltransferase inhibitors including I-CBP112 and C646 [49, 50] or therapies targeting other key PCa mutations, disruption of the ERG-BRD4 interaction may prove highly effective for a subset of advanced PCa.